Search results for "FACTOR"

showing 10 items of 17757 documents

Geriatric assessment and biomarkers in patients with metastatic breast cancer receiving first-line mono-chemotherapy: Results from the randomized pha…

2017

Abstract Objectives To determine predictive/prognostic factors for patients with metastatic breast cancer (MBC) receiving first-line monochemotherapy using biomarker analysis and geriatric assessment (GA). Materials and Methods Karnofsky Performance Status (KPS) and GA as clinical parameters, and prognostic inflammatory and nutritional index (PINI), and Glasgow prognostic score (GPS) as biomarkers were analyzed for association with clinical outcome within the randomized phase III PEg-LIposomal Doxorubicin vs. CApecitabin iN MBC (PELICAN) trial of first-line pegylated liposomal doxorubicin (PLD) or capecitabine. Results Of 210 patients, 38% were > 65 years old. GA (n = 152) classified 74% as…

0301 basic medicineOncologymedicine.medical_specialtyMultivariate analysisAnthracyclinemedicine.medical_treatmentBreast NeoplasmsPolyethylene GlycolsCapecitabine03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansDoxorubicinKarnofsky Performance StatusGeriatric AssessmentCapecitabineAgedChemotherapyFrailtybusiness.industryAge FactorsGeriatric assessmentMiddle Agedmedicine.diseaseMetastatic breast cancer030104 developmental biologyTreatment OutcomeOncologyDoxorubicin030220 oncology & carcinogenesisDisease ProgressionBiomarker (medicine)FemaleGeriatrics and GerontologybusinessBiomarkersmedicine.drugJournal of geriatric oncology
researchProduct

Imaging correlates of behavioral impairments: An experimental PET study in the rat pilocarpine epilepsy model

2018

Abstract Psychiatric comorbidities are prevalent in patients with epilepsy and greatly contribute to the overall burden of disease. The availability of reliable biomarkers to diagnose epilepsy-associated comorbidities would allow for effective treatment and improved disease management. Due to their non-invasive nature, molecular imaging techniques such as positron emission tomography (PET) are ideal tools to measure pathologic changes. In the current study we investigated the potential of [18F]fluoro-2-deoxy- d -glucose ([18F]FDG) and 2′-methoxyphenyl-(N-2′-pyridinyl)-p-18F-fluoro-benzamidoethylpiperazine ([18F]MPPF) as imaging correlates of neurobehavioral comorbidities in the pilocarpine …

0301 basic medicineOncologymedicine.medical_specialtyNeurologyEpileptogenesislcsh:RC321-571Rats Sprague-Dawley03 medical and health sciencesEpilepsychemistry.chemical_compound0302 clinical medicineNeurotrophic factorsInternal medicineMedicineAnimalsInterpersonal RelationsAnimal modellcsh:Neurosciences. Biological psychiatry. NeuropsychiatryBehaviorEpilepsymedicine.diagnostic_testbusiness.industryMental DisordersPilocarpinemedicine.diseaseRatsDisease Models Animal030104 developmental biologyBDNFPETchemistryNeurologyPositron emission tomographyPilocarpinePositron-Emission TomographyReceptor Serotonin 5-HT1ABiomarker (medicine)Female[18F]MPPFMPPF[18F]FDGbusiness030217 neurology & neurosurgerymedicine.drug
researchProduct

An update on intracerebral stem cell grafts.

2018

Introduction: Primary neurological disorders are notoriously debilitating and deadly, and over the past four decades stem cell therapy has emerged as a promising treatment. Translation of stem cell therapies from the bench to the clinic requires a better understanding of delivery protocols, safety profile, and efficacy in each disease. Areas covered: In this review, benefits and risks of intracerebral stem cell transplantation are presented for consideration. Milestone discoveries in stem cell applications are reviewed to examine the efficacy and safety of intracerebral stem cell transplant therapy for disorders of the central nervous system and inform design of translatable protocols for c…

0301 basic medicineOncologymedicine.medical_specialtyParkinson's diseaseTraumatic brain injurymedicine.medical_treatmentmulti-system atrophyNeuroprotection03 medical and health sciencesGraft vs Host Reaction0302 clinical medicineHuntington's diseaseCentral Nervous System DiseasesRisk FactorsInternal medicineMedicineAnimalsHumansPharmacology (medical)amyotrophic lateral sclerosiAmyotrophic lateral sclerosisStem cellbusiness.industryGeneral NeuroscienceMultiple sclerosistraumatic brain injuryStem-cell therapymedicine.diseasestroke030104 developmental biologyBlood-Brain Barriermultiple sclerosiParkinson’s diseaseneuroprotectionNeurology (clinical)Stem cellbusiness030217 neurology & neurosurgeryHuntington’s diseaseStem Cell TransplantationExpert review of neurotherapeutics
researchProduct

CXC chemokine ligand 4 (CXCL4) is predictor of tumour angiogenic activity and prognostic biomarker in non-small cell lung cancer (NSCLC) patients und…

2016

AbstractObjective: To evaluate the association of CXC chemokine ligand 4 (CXCL4) plasma levels with tumour angiogenesis in non-small cell lung cancer (NSCLC) and to assess association of CXCL4 with clinical outcomes.Patients and methods: Fifty patients with early stage NSCLC who underwent pulmonary resection. CXCL4 levels were analysed by ELISA. Angiogenesis was assessed by immunohistochemistry, and microvessel density (MVD) count.Results: There was positive correlation between MVD and CXCL4 levels. Patients with higher CXCL4 levels had worse overall and disease-free survival.Conclusions: Plasma levels of CXCL4 are associated with tumour vascularity. Increased CXCL4 levels in NSCLC patients…

0301 basic medicineOncologymedicine.medical_specialtyPathologyChemokineLung NeoplasmsAngiogenesisHealth Toxicology and MutagenesisClinical Biochemistrynon-small cell lung cancer (NSCLC)Platelet Factor 4BiochemistryDisease-Free Survival03 medical and health sciences0302 clinical medicineVascularityInternal medicineCarcinoma Non-Small-Cell LungmedicineHumansStage (cooking)biologyNeovascularization Pathologicbusiness.industryLigand (biochemistry)medicine.disease030104 developmental biologyTreatment Outcome030220 oncology & carcinogenesisbiology.proteinImmunohistochemistrymedicine.symptomNeoplasm Recurrence LocalbusinessPlatelet factor 4BiomarkersBiomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
researchProduct

Oncofetal gene SALL4 and prognosis in cancer: A systematic review with meta-analysis

2016

The Spalt-Like Transcription Factor 4 (SALL4) oncogene plays a central function in embryo-fetal development and is absent in differentiated tissues. Evidence suggests that it can be reactivated in several cancers worsening the prognosis. We aimed at investigating the risk associated with SALL4 reactivation for all-cause mortality and recurrence in cancer using the current literature. A PubMed and SCOPUS search until 1st September 2016 was performed, focusing on perspective studies reporting prognostic parameters in cancer data. In addition, 17 datasets of different cancer types from The Cancer Genome Atlas were considered. A total of 9,947 participants across 40 cohorts, followed-up for abo…

0301 basic medicineOncologymedicine.medical_specialtyPediatricsmedicine.medical_treatmentDiseaseTargeted therapySALL4; cancer; meta-analysis; prognosis; targeted therapy; Humans; Neoplasms; Prognosis; Transcription FactorsCancer; Meta-analysis; Prognosis; SALL4; Targeted therapy; Oncology03 medical and health sciences0302 clinical medicineSALL4Internal medicineNeoplasmsmedicinecancerHumansSALL4 cancer prognosis meta-analysis targeted therapySALL4business.industryConfoundingHazard ratiotargeted therapyConfidence intervaleye diseases3. Good healthmeta-analysis030104 developmental biologyOncology030220 oncology & carcinogenesisMeta-analysisRelative riskprognosisbusinessResearch PaperTranscription Factors
researchProduct

Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation

2016

// Nicoletta Staropoli 1, * , Domenico Ciliberto 1, * , Silvia Chiellino 1 , Francesca Caglioti 1 , Teresa Del Giudice 1 , Simona Gualtieri 1 , Angela Salvino 1 , Alessandra Strangio 1 , Cirino Botta 1 , Sandro Pignata 2 , Pierfrancesco Tassone 1, * , Pierosandro Tagliaferri 1, * 1 Department of Experimental and Clinical Medicine, Magna Graecia University, Catanzaro, Italy 2 Department of Gynecologic and Urologic Oncology, Fondazione Pascale, National Cancer Institute of Naples, Naples, Italy * These authors have contributed equally to this work Correspondence to: Pierosandro Tagliaferri, email: tagliaferri@unicz.it Keywords: ovarian cancer, targeted therapy, systemic chemotherapy, systemat…

0301 basic medicineOncologymedicine.medical_specialtyTime FactorsBevacizumabmedicine.medical_treatmentAngiogenesis InhibitorsDisease-Free SurvivalTargeted therapyTargeted therapy03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRisk FactorsOvarian cancerInternal medicineBiomarkers TumorOdds RatiomedicineHumansMeta-analysiMolecular Targeted TherapyPrecision MedicineSystemic chemotherapyOvarian Neoplasmsbusiness.industryPatient SelectionHazard ratioCancermedicine.diseaseCarboplatinmeta-analysisClinical trialTreatment Outcome030104 developmental biologyOncologychemistryDrug Resistance Neoplasm030220 oncology & carcinogenesisMeta-analysisDisease ProgressionSystematic reviewFemalePersonalized medicinebusinessResearch PaperSignal Transductionmedicine.drug
researchProduct

A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations

2021

Treatment of advanced non-small cell lung cancer (NSCLC) has radically improved in the last years due to development and clinical approval of highly effective agents including immune checkpoint inhibitors (ICIs) and oncogene-directed therapies. Molecular profiling of lung cancer samples for activated oncogenes, including epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1) and BRAF, is routinely performed to select the most appropriate up-front treatment. However, the identification of new therapeutic targets remains a high priority. Recently, MET exon 14 skipping mutations have emerged as novel actionable oncogenic alterations in NSCLC, sensiti…

0301 basic medicineOncologymedicine.medical_specialtybiologybusiness.industryCancernon-small cell lung cancer (NSCLC)medicine.disease03 medical and health sciencesExon030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicineROS1biology.proteinMET; MET exon 14 skipping mutations; MET-tyrosine kinase inhibitors (TKIs); Non-small cell lung cancer (NSCLC)MedicineAnaplastic lymphoma kinaseEpidermal growth factor receptorbusinessLung cancerTyrosine kinase
researchProduct

Prognostic Significance of Survivin Expression in Patients with Ovarian Carcinoma: A Meta-Analysis

2021

Background: Survivin belongs to the protein family of inhibitors of apoptosis (IAP) and is a regulator of the cell cycle and apoptosis. The aim of this study was to assess the clinical and prognostic significance of expression survivin in patients with ovarian cancer. Methods: We systematically searched for articles in PubMed, the American Chemical Society (Publications), Medline, the Royal Society of Chemistry, Scopus and the Web of Science. Patient clinical data, overall survival (OS), disease-free survival (DFS), and survivin expression were extracted from individual studies. We performed statistical analysis using the STATA 16 package. Eighteen publications containing data from 2233 pat…

0301 basic medicineOncologymedicine.medical_specialtylcsh:MedicineReviewsurvivin03 medical and health sciences0302 clinical medicineInternal medicineOvarian carcinomaSurvivinmedicineprognostic factorProspective cohort studybusiness.industrylcsh:RGeneral MedicineOdds ratiomedicine.diseasemeta-analysisovarian cancer030104 developmental biology030220 oncology & carcinogenesisRelative riskMeta-analysisBiomarker (medicine)Ovarian cancerbusinessJournal of Clinical Medicine
researchProduct

A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients

2019

Background Pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) varies between 30 and 40% approximately. To provide further insight into the prediction of pCR, we evaluated the role of an epigenetic methylation-based signature. Methods Epigenetic assessment of DNA extracted from biopsy archived samples previous to NAC from TNBC patients was performed. Patients included were categorized according to previous response to NAC in responder (pCR or residual cancer burden, RCB = 0) or non-responder (non-pCR or RCB > 0) patients. A methyloma study was performed in a discovery cohort by the Infinium HumanMethylation450 BeadChip (450K arra…

0301 basic medicineOncologymedicine.medical_treatmentADNlcsh:MedicineTriple Negative Breast NeoplasmsEpigenesis Genetic0302 clinical medicineGenetics (clinical)Triple-negative breast cancermedicine.diagnostic_testHigh-Throughput Nucleotide SequencingNuclear ProteinsMethylationMiddle AgedNeoadjuvant TherapyGene Expression Regulation NeoplasticTreatment OutcomeMyogenic Regulatory FactorsEfectes secundaris dels medicaments030220 oncology & carcinogenesisCohortFemaleTaxoidsMetilacióMicrotubule-Associated ProteinsAdultmedicine.medical_specialtylcsh:QH426-470MethylationMinor Histocompatibility Antigens03 medical and health sciencesBreast cancerTriple-negative breast cancerInternal medicineCell Line TumorBiopsyGeneticsmedicineHumansEpigeneticsMolecular BiologyEpigenetic signatureAgedChemotherapybusiness.industryGene Expression ProfilingResearchlcsh:RSequence Analysis DNADNADNA Methylationmedicine.diseaseHuman geneticsRepressor Proteinslcsh:Genetics030104 developmental biologyDrug side effectsbusinessPredictionDevelopmental Biology
researchProduct

Epigenomic landscape of human colorectal cancer unveils an aberrant core of pan-cancer enhancers orchestrated by YAP/TAZ

2021

Cancer is characterized by pervasive epigenetic alterations with enhancer dysfunction orchestrating the aberrant cancer transcriptional programs and transcriptional dependencies. Here, we epigenetically characterize human colorectal cancer (CRC) using de novo chromatin state discovery on a library of different patient-derived organoids. By exploring this resource, we unveil a tumor-specific deregulated enhancerome that is cancer cell-intrinsic and independent of interpatient heterogeneity. We show that the transcriptional coactivators YAP/TAZ act as key regulators of the conserved CRC gained enhancers. The same YAP/TAZ-bound enhancers display active chromatin profiles across diverse human t…

0301 basic medicineOrganoidEpigenomicsTranscription FactorGeneral Physics and AstronomyColorectal NeoplasmAdaptor Proteins Signal Transducing; Colorectal Neoplasms; Gene Expression Regulation Neoplastic; Histone Code; Humans; Models Genetic; Organoids; RNA-Seq; Single-Cell Analysis; Trans-Activators; Transcription Factors; Tumor Cells Cultured; Enhancer Elements Genetic; Epigenesis GeneticEpigenesis Genetic0302 clinical medicineModelsAdaptor Proteins Signal Transducing Colorectal Neoplasms Gene Expression Regulation NeoplasticHistone Code Humans Models Genetic Organoids RNA-Seq Single-Cell Analysis Trans-Activators Transcription Factors Tumor Cells Cultured Enhancer Elements Genetic Epigenesis GeneticTumor Cells CulturedCancer genomicsHistone codeRNA-SeqEpigenomicsAdaptor Proteins Signal Transducing; Colorectal Neoplasms; Gene Expression Regulation Neoplastic; Histone Code; Humans; Models Genetic; Organoids; RNA-Seq; Single-Cell Analysis; Trans-Activators; Transcription Factors; Transcriptional Coactivator with PDZ-Binding Motif Proteins; Tumor Cells Cultured; YAP-Signaling Proteins; Enhancer Elements Genetic; Epigenesis GeneticMultidisciplinaryCulturedQAdaptor Proteins3. Good healthChromatinTumor CellsGene Expression Regulation NeoplasticHistone CodeOrganoidsSingle-Cell AnalysiEnhancer Elements GeneticTrans-Activator030220 oncology & carcinogenesisSingle-Cell AnalysisColorectal NeoplasmsHumanEnhancer ElementsScienceTumour heterogeneityBiologyGeneral Biochemistry Genetics and Molecular BiologyArticle03 medical and health sciencesGeneticmedicineHumansEpigeneticsEnhancerTranscription factorAdaptor Proteins Signal TransducingNeoplasticModels GeneticSignal TransducingCancerYAP-Signaling ProteinsGeneral Chemistrymedicine.diseaseColorectal cancerdigestive system diseases030104 developmental biologyGene Expression RegulationTranscriptional Coactivator with PDZ-Binding Motif ProteinsCancer cellCancer researchTrans-ActivatorsEpigenesisTranscription Factors
researchProduct